Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil in Migraine Pretreated With Erenumab
NCT05889455Completed
- Sponsor
- Dansk Hovedpinecenter
- Start
- Apr 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of ASP-001 (2 arms), sponsored by Dansk Hovedpinecenter. Primary endpoint: Incidence of migraine attack at 12 hours. Started Apr 2023; status: completed.
02
Drugs
ASP-001
Beyond the preview
Go deeper on NCT05889455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05889455.